Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
The Journal of Infectious Diseases|April 6, 2024
What Is the Economic Benefit of Annual COVID-19 Vaccination From the Adult Individual Perspective?Sarah M Bartsch, Kelly J O'Shea, Colleen Weatherwax, et al.
Human Vaccines & Immunotherapeutics|February 4, 2016
Expression and purification of an engineered, yeast-expressed Leishmania donovani nucleoside hydrolase with immunogenic propertiesElissa M Hudspeth, Qian Wang, Christopher A Seid, et al.
Frontiers in Immunology|October 6, 2025
Heterologous prime-pull mucosal vaccination with an adjuvanted RBD vaccine elicits robust IgA production and protects against SARS-CoV-2Allyson H Hirsch, Calder R Ellsworth, William A Lewis, et al.
Vaccines|February 28, 2023
A Data-Driven Approach to Construct a Molecular Map of <i>Trypanosoma cruzi</i> to Identify Drugs and Vaccine TargetsSwarsat Kaushik Nath, Preeti Pankajakshan, Trapti Sharma, et al.
Biochimica Et Biophysica Acta. General Subjects|March 18, 2021
Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidateWen-Hsiang Chen, Junfei Wei, Rakhi Tyagi Kundu, et al.
Scientific Reports|September 3, 2021
Identification of vaccine targets in pathogens and design of a vaccine using computational approachesKamal Rawal, Robin Sinha, Bilal Ahmed Abbasi, et al.
NPJ Vaccines|July 21, 2024
A trivalent protein-based pan-Betacoronavirus vaccine elicits cross-neutralizing antibodies against a panel of coronavirus pseudovirusesSyamala Rani Thimmiraju, Rakesh Adhikari, JeAnna R Redd, et al.
Protein Expression and Purification|October 24, 2021
Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidateWen-Hsiang Chen, Jeroen Pollet, Ulrich Strych, et al.
The Journal of Infectious Diseases|January 22, 2025
The Current and Future Burden of Long COVID in the United States (U.S.)Sarah M Bartsch, Kevin L Chin, Ulrich Strych, et al.
Human Vaccines & Immunotherapeutics|April 13, 2021
SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in miceJeroen Pollet, Wen-Hsiang Chen, Leroy Versteeg, et al.
Pageof 10